Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hepatitis b patients under the microscope: new study observes Real-World treatments

NCT ID NCT03692897

Knowledge-focused Sponsor: Target PharmaSolutions, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study observed over 1,700 adults with chronic hepatitis B in the US and Canada to understand how the disease progresses and how treatments are used in everyday medical practice. Researchers collected data from both academic and community clinics to build a real-world picture of patient care. The study did not test any new drug or intervention, but aimed to improve knowledge about managing hepatitis B.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,708 people

The number who actually took part.

Started

Oct 2018

Finished

Sep 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Up to 5,000 adult Chronic Hepatitis B (CHB) patients in the US and Canada; the first 500 patients enrolled were patients in the US with a medical history of tenofovir alafenamide (TAF) use for the treatment of chronic HBV.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion 1. Male or female patients, age ≥18 years 2. Being managed for chronic hepatitis B (CHB), including patients who have achieved functional cure and patients with concurrent delta hepatitis Exclusion 1. Inability to provide written informed consent 2. Known history of Human Immunodeficiency Virus (HIV) 3. History of liver transplantation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Delta hepatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatitis hepatitis B virus infection hepatitis D virus infection liver disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatitis Hepatitis B Liver diseases

Contacts and locations

Locations

  • Asian Pacific Liver Center at Coalition of Inclusive Medicine

    Los Angeles, California, 90020, United States

  • Atlanta Gastroenterology

    Atlanta, Georgia, 30342, United States

  • Banner University Medical Center Phoenix

    Phoenix, Arizona, 85006, United States

  • Bon Secours Liver Institute of Richmond

    Richmond, Virginia, 23226, United States

  • California Liver Research Institute

    Pasadena, California, 91105, United States

  • Columbia University Medical Center

    New York, New York, 10032, United States

  • Consultative Gastroenterology

    Atlanta, Georgia, 30308, United States

  • Digestive and Liver Disease Specialist

    Norfolk, Virginia, 23502, United States

  • Dreamwork Medical, PLLC

    Flushing, New York, 11354, United States

  • Medstar Georgetown University Hospital

    Washington D.C., District of Columbia, 20007, United States

  • Mercy Medical Center

    Baltimore, Maryland, 21202, United States

  • Minnesota Gastroenterology, P.A.

    Plymouth, Minnesota, 55446, United States

  • NYU Langone Health

    New York, New York, 10016, United States

  • Northwell Health Center for Liver Diseases and Transplantation

    Manhasset, New York, 11030, United States

  • Rush Universtiy Medical Center

    Chicago, Illinois, 60612, United States

  • Rutgers, Robert Wood Johnson Medical School

    New Brunswick, New Jersey, 08901, United States

  • Silicon Valley Research Institute

    San Jose, California, 95128, United States

  • Stanford University

    Redwood City, California, 94063, United States

  • Swedish Organ Transplant and Liver Center

    Seattle, Washington, 98104, United States

  • UC Davis GI/Hepatology Clinical Trials Unit

    Sacramento, California, 95817, United States

  • UHN Toronto General Hospital

    Toronto, Ontario, M5G 2C4, Canada

  • UNC Liver Center

    Chapel Hill, North Carolina, 27599, United States

  • UT Southwestern Medical Center

    Dallas, Texas, 75390, United States

  • University of Chicago

    Chicago, Illinois, 60637, United States

  • University of Florida

    Gainesville, Florida, 32610-0272, United States

  • University of Miami, Schiff Center for Liver Disease

    Miami, Florida, 33136, United States

  • University of Michigan

    Ann Arbor, Michigan, 48109, United States

  • University of Washington/Harborview Medical Center

    Seattle, Washington, 98104, United States

  • Virginia Commonwealth University

    Richmond, Virginia, 23298, United States

  • Weill Cornell Medical College

    New York, New York, 10021, United States

  • Yale University Digestive Diseases

    New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.